BibTex RIS Kaynak Göster

-

Yıl 2007, Cilt: 20 Sayı: 2, 98 - 103, 25.06.2015

Öz

-

Kaynakça

  • Guyatt G, Veldhuyzen Van Zanten S, Feeny D, Patrick
  • D. Measuring quality of life in clinical trials: a taxonomy
  • and review. Can Med Assoc J 1989; 140: 1441-1448.
  • Lauper P, Versteegen U. The importance of quality of
  • life in policy decisions: new end points in medical
  • outcome assessment. Pharm Med 1992; 5: 43-50.
  • Schumacher A, Kessler T, Riedel A, Buchner T, van de
  • Loo J. Quality of life and coping with illness in patients
  • with acute myeloid leukemia. Psychother Psychosom
  • Med Psychol 1996; 46: 385-390.
  • Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S,
  • Cavallin-Stahl E. Health-related quality of life and its
  • potential prognostic implications in patients with
  • aggressive lymphoma: a Nordic Lymphoma Group Trial.
  • Medical Oncology 2001; 18: 85-94.
  • Persson L, Larsson G, Ohlsson O, Hallberg IR. Acute
  • leukemia or highly malignant lymphoma patients’
  • quality of life over two years: a pilot study. Eur J of
  • Cancer Care 2001; 10: 36-47.
  • Cella DF, Tulsky S. Measuring quality of life today:
  • methodological aspects. Oncology 1990; 4: 29-38.
  • The WHOQOL Group. The World Health Organization
  • quality of life assessment (WHOQOL): position paper
  • from the World Health Organization. Soc Sci Med 1995;
  • : 1403-1409.
  • Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson
  • BD. Quality-of-life assessment in cancer treatment
  • protocols: research issues in protocol development. J
  • Natl Cancer Inst 1992; 84: 575-579.
  • Cella DF. Quality of life: the concept. J Palliat Care
  • ; 8: 8-13.
  • Kaasa S, Loge JH. Quality of life in palliative care:
  • principles and practice. Palliat Med 2003; 17: 11-20.
  • Wierzbicka M, Kusnierkiewicz M, Wojtowicz JG,
  • Maune S, Szyfter W. The quality of life in head and neck
  • cancer patients: description of randomized examination
  • formula based on standardized questionnaires EORTC
  • QLQ C-30, EORTC QTQ-H-N35 and Kiel
  • Questionnaire. Otolaryngol Pol 2001; 55: 287-292 [in
  • Polish].
  • Kaasa S, Bjordal K, Aaronson N, et al. The EORTC
  • core quality of life questionnaire (QLQ-C30): validity
  • and reliability when analyzed with patients treated with
  • palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-
  • -
  • Kobayashi K, Takeda F, Teramukai S, et al. A crossvalidation
  • of the European Organization for Research
  • and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30)
  • for Japanese with lung cancer. Eur J Cancer 1998; 34:
  • –815.
  • Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A.
  • Modification of the EORTC QLQ-C30 (version 2.0)
  • based on content validity and reliability testing in large
  • samples of patients with cancer. The Study Group on
  • Quality of Life of the EORTC and the Symptom Control
  • and Quality of Life Committees of the NCI of Canada
  • Clinical Trials Group. Qual Life Res 1997; 6: 103-108.
  • Aaronson NK, Ahmedzai S, Bergman B, et al. The
  • European Organization for Research and Treatment of
  • Cancer QLQ-C30: a quality-of-life instrument for use in
  • international clinical trials in oncology. J Natl Cancer
  • Inst 1993; 85: 365-376.
  • Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al.
  • Development of a European Organization for Research
  • and Treatment of Cancer (EORTC) questionnaire
  • module to be used in quality of life assessments in head
  • and neck cancer patients. EORTC Quality of Life Study
  • Group. Acta Oncol 1994; 33: 879-885.
  • Bjordal K, de Graeff A, Fayers PM, et al. A 12 country
  • field study of the EORTC QLQ-C30 (version 3.0) and
  • the head and neck cancer specific module (EORTC
  • QLQ-H&N35) in head and neck patients. EORTC
  • Quality of Life Group. Eur J Cancer 2000; 36: 1796-
  • -
  • Blazeby JM, Alderson D, Winstone K, et al.
  • Development of an EORTC questionnaire module to be
  • used in quality of life assessment for patients with
  • oesophageal cancer. The EORTC Quality of Life Study
  • Group. Eur J Cancer 1996; 32A: 1912-1917.
  • Sprangers MA, Cull A, Groenvold M, Bjordal K,
  • Blazeby J, Aaronson NK. The European Organization
  • for Research and Treatment of Cancer approach to
  • developing questionnaire modules: an update and
  • overview. EORTC Quality of Life Study Group. Qual
  • Life Res 1998; 7: 291-300.
  • Schumacher A, Kessler T, Buchner T, Wewers D, van
  • de Loo J. Quality of life in adult patients with acute
  • myeloid leukemia receiving intensive and prolonged
  • chemotherapy-a longitudinal study. Leukemia 1998; 12:
  • -592.
  • Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in longterm
  • survivors of Hodgkin‘s lymphoma; a report from
  • the German Hodgkin Lymphoma Study Group (GHSG).
  • Eur J Cancer 2003; 39: 2179-2186.
  • Vogelzang NJ, Breitbart W, Cella D, et al. Patient,
  • caregiver, and oncologist perceptions of cancer-related
  • fatigue: results of a tripart assessment survey. The
  • Fatigue Coalition. Semin Hematol 1997; 34: 4-12.
  • Curt GA. The impact of fatigue on patients with cancer:
  • overview of FATIGUE 1 and 2. Oncologist 2000; 5
  • (Suppl 2): 9-12.

LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ

Yıl 2007, Cilt: 20 Sayı: 2, 98 - 103, 25.06.2015

Öz

Amaç: Kemoterapideki gelişmeler lenfomalı hastaların yaşam sürelerini önemli derecede uzatmıştır ve önemli sayıda hasta tedavi edilebilmektedir. Kemoterapi alan hastaların yaşam kalitelerinin değerlendirilmesi giderek daha fazla ilgi çeken bir konu olmuştur. Çalışmamızın amacı, lenfomalı hastalarda kemoterapinin yaşam kalitesine etkilerini değerlendirmektir. Gereç ve Yöntem: Haziran 2000-Ocak 2001 tarihleri arasında Çukurova Üniversitesi Tıp Fakültesi Onkoloji Bilim Dalı’nda Evre I lenfoma tanısı alan 49 hastaya kemoterapi öncesinde ve 2. kür sonrasında yaşam kalitesi anketi (EORTC QLQ C-30) uygulandı. Bulgular: Fiziksel aktivitelerin bazılarında, duygusal fonksiyonlar, ağrı ve halsizlik, dispne, iştahsızlık, uyku ve global yaşam kalitesinde tedavi sırasında anlamlı iyileşme saptandı. Kemoterapi, yaş, cinsiyet ve lenfoma tipi göz önüne alındığında, global yaşam kalitesini etkileyen en önemli faktör hastanın eğitim durumuydu. Sonuç: Çalışmamızın sonuçları, kemoterapi öncesindeki yaşam kalitesine kıyasla tedavi sonrası yaşam kalitesinde iyileşme olması nedeniyle, kemoterapi alma konusunda isteksiz olan hastalara yardımcı olmada kullanılabilir.

Anahtar Kelimeler: Lenfoma, Yaşam kalitesi, EORTC QLQ C-30, Adana

Kaynakça

  • Guyatt G, Veldhuyzen Van Zanten S, Feeny D, Patrick
  • D. Measuring quality of life in clinical trials: a taxonomy
  • and review. Can Med Assoc J 1989; 140: 1441-1448.
  • Lauper P, Versteegen U. The importance of quality of
  • life in policy decisions: new end points in medical
  • outcome assessment. Pharm Med 1992; 5: 43-50.
  • Schumacher A, Kessler T, Riedel A, Buchner T, van de
  • Loo J. Quality of life and coping with illness in patients
  • with acute myeloid leukemia. Psychother Psychosom
  • Med Psychol 1996; 46: 385-390.
  • Jerkeman M, Kaasa S, Hjermstad M, Kvaloy S,
  • Cavallin-Stahl E. Health-related quality of life and its
  • potential prognostic implications in patients with
  • aggressive lymphoma: a Nordic Lymphoma Group Trial.
  • Medical Oncology 2001; 18: 85-94.
  • Persson L, Larsson G, Ohlsson O, Hallberg IR. Acute
  • leukemia or highly malignant lymphoma patients’
  • quality of life over two years: a pilot study. Eur J of
  • Cancer Care 2001; 10: 36-47.
  • Cella DF, Tulsky S. Measuring quality of life today:
  • methodological aspects. Oncology 1990; 4: 29-38.
  • The WHOQOL Group. The World Health Organization
  • quality of life assessment (WHOQOL): position paper
  • from the World Health Organization. Soc Sci Med 1995;
  • : 1403-1409.
  • Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson
  • BD. Quality-of-life assessment in cancer treatment
  • protocols: research issues in protocol development. J
  • Natl Cancer Inst 1992; 84: 575-579.
  • Cella DF. Quality of life: the concept. J Palliat Care
  • ; 8: 8-13.
  • Kaasa S, Loge JH. Quality of life in palliative care:
  • principles and practice. Palliat Med 2003; 17: 11-20.
  • Wierzbicka M, Kusnierkiewicz M, Wojtowicz JG,
  • Maune S, Szyfter W. The quality of life in head and neck
  • cancer patients: description of randomized examination
  • formula based on standardized questionnaires EORTC
  • QLQ C-30, EORTC QTQ-H-N35 and Kiel
  • Questionnaire. Otolaryngol Pol 2001; 55: 287-292 [in
  • Polish].
  • Kaasa S, Bjordal K, Aaronson N, et al. The EORTC
  • core quality of life questionnaire (QLQ-C30): validity
  • and reliability when analyzed with patients treated with
  • palliative radiotherapy. Eur J Cancer 1995; 31A: 2260-
  • -
  • Kobayashi K, Takeda F, Teramukai S, et al. A crossvalidation
  • of the European Organization for Research
  • and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30)
  • for Japanese with lung cancer. Eur J Cancer 1998; 34:
  • –815.
  • Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A.
  • Modification of the EORTC QLQ-C30 (version 2.0)
  • based on content validity and reliability testing in large
  • samples of patients with cancer. The Study Group on
  • Quality of Life of the EORTC and the Symptom Control
  • and Quality of Life Committees of the NCI of Canada
  • Clinical Trials Group. Qual Life Res 1997; 6: 103-108.
  • Aaronson NK, Ahmedzai S, Bergman B, et al. The
  • European Organization for Research and Treatment of
  • Cancer QLQ-C30: a quality-of-life instrument for use in
  • international clinical trials in oncology. J Natl Cancer
  • Inst 1993; 85: 365-376.
  • Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al.
  • Development of a European Organization for Research
  • and Treatment of Cancer (EORTC) questionnaire
  • module to be used in quality of life assessments in head
  • and neck cancer patients. EORTC Quality of Life Study
  • Group. Acta Oncol 1994; 33: 879-885.
  • Bjordal K, de Graeff A, Fayers PM, et al. A 12 country
  • field study of the EORTC QLQ-C30 (version 3.0) and
  • the head and neck cancer specific module (EORTC
  • QLQ-H&N35) in head and neck patients. EORTC
  • Quality of Life Group. Eur J Cancer 2000; 36: 1796-
  • -
  • Blazeby JM, Alderson D, Winstone K, et al.
  • Development of an EORTC questionnaire module to be
  • used in quality of life assessment for patients with
  • oesophageal cancer. The EORTC Quality of Life Study
  • Group. Eur J Cancer 1996; 32A: 1912-1917.
  • Sprangers MA, Cull A, Groenvold M, Bjordal K,
  • Blazeby J, Aaronson NK. The European Organization
  • for Research and Treatment of Cancer approach to
  • developing questionnaire modules: an update and
  • overview. EORTC Quality of Life Study Group. Qual
  • Life Res 1998; 7: 291-300.
  • Schumacher A, Kessler T, Buchner T, Wewers D, van
  • de Loo J. Quality of life in adult patients with acute
  • myeloid leukemia receiving intensive and prolonged
  • chemotherapy-a longitudinal study. Leukemia 1998; 12:
  • -592.
  • Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in longterm
  • survivors of Hodgkin‘s lymphoma; a report from
  • the German Hodgkin Lymphoma Study Group (GHSG).
  • Eur J Cancer 2003; 39: 2179-2186.
  • Vogelzang NJ, Breitbart W, Cella D, et al. Patient,
  • caregiver, and oncologist perceptions of cancer-related
  • fatigue: results of a tripart assessment survey. The
  • Fatigue Coalition. Semin Hematol 1997; 34: 4-12.
  • Curt GA. The impact of fatigue on patients with cancer:
  • overview of FATIGUE 1 and 2. Oncologist 2000; 5
  • (Suppl 2): 9-12.
Toplam 101 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Esra Saatçi

Yüksel Koçak Bu kişi benim

Nafiz Bozdemir Bu kişi benim

Ersin Akpınar Bu kişi benim

Zeynep Kalaylıoğlu-wheeler Bu kişi benim

Yayımlanma Tarihi 25 Haziran 2015
Yayımlandığı Sayı Yıl 2007 Cilt: 20 Sayı: 2

Kaynak Göster

APA Saatçi, E., Koçak, Y., Bozdemir, N., Akpınar, E., vd. (2015). LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ. Marmara Medical Journal, 20(2), 98-103.
AMA Saatçi E, Koçak Y, Bozdemir N, Akpınar E, Kalaylıoğlu-wheeler Z. LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ. Marmara Med J. Ağustos 2015;20(2):98-103.
Chicago Saatçi, Esra, Yüksel Koçak, Nafiz Bozdemir, Ersin Akpınar, ve Zeynep Kalaylıoğlu-wheeler. “LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ”. Marmara Medical Journal 20, sy. 2 (Ağustos 2015): 98-103.
EndNote Saatçi E, Koçak Y, Bozdemir N, Akpınar E, Kalaylıoğlu-wheeler Z (01 Ağustos 2015) LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ. Marmara Medical Journal 20 2 98–103.
IEEE E. Saatçi, Y. Koçak, N. Bozdemir, E. Akpınar, ve Z. Kalaylıoğlu-wheeler, “LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ”, Marmara Med J, c. 20, sy. 2, ss. 98–103, 2015.
ISNAD Saatçi, Esra vd. “LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ”. Marmara Medical Journal 20/2 (Ağustos 2015), 98-103.
JAMA Saatçi E, Koçak Y, Bozdemir N, Akpınar E, Kalaylıoğlu-wheeler Z. LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ. Marmara Med J. 2015;20:98–103.
MLA Saatçi, Esra vd. “LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ”. Marmara Medical Journal, c. 20, sy. 2, 2015, ss. 98-103.
Vancouver Saatçi E, Koçak Y, Bozdemir N, Akpınar E, Kalaylıoğlu-wheeler Z. LENFOMALI HASTALARDA KEMOTERAPİNİN YAŞAM KALİTESİNE ETKİSİ. Marmara Med J. 2015;20(2):98-103.